|
AU2002950217A0
(en)
|
2002-07-16 |
2002-09-12 |
Prana Biotechnology Limited |
8- Hydroxy Quinoline Derivatives
|
|
CN101534826A
(zh)
*
|
2006-04-14 |
2009-09-16 |
普拉纳生物技术有限公司 |
治疗与年龄相关的黄斑变性（amd）的方法
|
|
US8163779B2
(en)
*
|
2006-12-20 |
2012-04-24 |
Takeda San Diego, Inc. |
Glucokinase activators
|
|
US9321730B2
(en)
*
|
2007-08-21 |
2016-04-26 |
The Hong Kong Polytechnic University |
Method of making and administering quinoline derivatives as anti-cancer agents
|
|
SG187502A1
(en)
|
2008-02-01 |
2013-02-28 |
Takeda Pharmaceutical |
Oxim derivatives as hsp90 inhibitors
|
|
GB0806794D0
(en)
*
|
2008-04-15 |
2008-05-14 |
Ludwig Inst Cancer Res |
Therapeutic compounds
|
|
AU2009282480B2
(en)
*
|
2008-08-11 |
2015-05-07 |
Children's Medical Center Corporation |
Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
|
|
WO2010071944A1
(en)
*
|
2008-12-24 |
2010-07-01 |
Prana Biotechnology Limited |
Quinazolinone compounds
|
|
US10253020B2
(en)
|
2009-06-12 |
2019-04-09 |
Abivax |
Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
WO2012083866A1
(en)
*
|
2010-12-22 |
2012-06-28 |
The Hong Kong Polytechnic University |
Quinoline derivatives as anti-cancer agents
|
|
EP2565186A1
(en)
*
|
2011-09-02 |
2013-03-06 |
Hybrigenics S.A. |
Selective and reversible inhibitors of ubiquitin specific protease 7
|
|
FR2984317B1
(fr)
*
|
2011-12-20 |
2015-02-27 |
Univ Rennes |
Composes chelateurs de metal presentant au moins une chaine polyaminee.
|
|
US10155742B2
(en)
|
2012-01-13 |
2018-12-18 |
President And Fellows Of Harvard College |
Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
KR101685862B1
(ko)
|
2012-12-27 |
2016-12-20 |
에프. 호프만-라 로슈 아게 |
Comt 억제제
|
|
EP2757161A1
(en)
|
2013-01-17 |
2014-07-23 |
Splicos |
miRNA-124 as a biomarker of viral infection
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US10005739B2
(en)
|
2013-10-23 |
2018-06-26 |
Chugai Seiyaku Kabushiki Kaisha |
Quinazolinone and isoquinolinone derivative
|
|
EP2974729A1
(en)
|
2014-07-17 |
2016-01-20 |
Abivax |
Quinoline derivatives for use in the treatment of inflammatory diseases
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CA2968090A1
(en)
*
|
2014-12-02 |
2016-06-09 |
Prana Biotechnology Limited |
4h-pyrido[1,2-a]pyrimidin-4-one compounds
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
JP7402792B2
(ja)
*
|
2017-09-26 |
2023-12-21 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
EP3801525A4
(en)
|
2018-06-08 |
2022-03-23 |
The General Hospital Corporation |
PROLYL TRNA SYNTHETASE INHIBITORS
|
|
EP3870179A4
(en)
|
2018-10-22 |
2022-11-23 |
Dana Farber Cancer Institute, Inc. |
USP7 ESCAPEMENT
|
|
EP3669873A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Quinoline derivatives for use ine the traeatment of inflammation diseases
|
|
CN111471012B
(zh)
*
|
2019-01-23 |
2023-04-25 |
鲁南制药集团股份有限公司 |
一种蜈蚣喹啉类化合物、制备方法及其应用
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN110240590B
(zh)
*
|
2019-07-16 |
2025-09-19 |
广州新民培林医药科技有限公司 |
一类嘧啶喹啉衍生物及其制备方法和应用
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN115151540A
(zh)
|
2019-12-02 |
2022-10-04 |
风暴治疗有限公司 |
作为mettl3抑制剂的多杂环化合物
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US11691971B2
(en)
|
2020-06-19 |
2023-07-04 |
Incyte Corporation |
Naphthyridinone compounds as JAK2 V617F inhibitors
|
|
WO2021257863A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Pyrrolotriazine compounds as jak2 v617f inhibitors
|
|
CR20230057A
(es)
|
2020-07-02 |
2023-08-15 |
Incyte Corp |
Compuestos tríciclicos de urea como inhibidores de jak2 v617f
|
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
|
US11661422B2
(en)
|
2020-08-27 |
2023-05-30 |
Incyte Corporation |
Tricyclic urea compounds as JAK2 V617F inhibitors
|
|
US11919908B2
(en)
|
2020-12-21 |
2024-03-05 |
Incyte Corporation |
Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
|
|
AR125273A1
(es)
|
2021-02-25 |
2023-07-05 |
Incyte Corp |
Lactamas espirocíclicas como inhibidores de jak2 v617f
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
CN113214249B
(zh)
*
|
2021-04-23 |
2023-09-19 |
成都大学 |
吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
PT4426434T
(pt)
|
2021-11-02 |
2025-11-24 |
Flare Therapeutics Inc |
Agonistas inversos de pparg e suas utilizações
|
|
AU2023235313A1
(en)
|
2022-03-17 |
2024-10-03 |
Incyte Corporation |
Tricyclic urea compounds as jak2 v617f inhibitors
|
|
CN116410132B
(zh)
*
|
2023-02-23 |
2024-07-09 |
广东工业大学 |
一种8-羟基喹啉类化合物及其制备方法和在制备抗肿瘤药物上的应用
|